Cisplatin + RT for Triple Negative Breast Cancer
Status: | Active, not recruiting |
---|---|
Conditions: | Breast Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 11/21/2018 |
Start Date: | October 2012 |
End Date: | October 2023 |
A Phase I Dose-Escalation Study of Cisplatin and Radiation Therapy for Patients With Triple Negative Breast Cancer
This is a Phase I dose escalation study of cisplatin and concurrent radiation in patients
with ER negative, PR negative and HER2 negative breast cancer who have undergone
breast-conserving surgery or mastectomy.
Primary objective: To assess the safety, tolerability, and maximum tolerated dose (MTD) of
cisplatin when given concurrently with radiation therapy for participants with Stage II or
III breast cancer who have undergone breast conserving surgery or mastectomy
with ER negative, PR negative and HER2 negative breast cancer who have undergone
breast-conserving surgery or mastectomy.
Primary objective: To assess the safety, tolerability, and maximum tolerated dose (MTD) of
cisplatin when given concurrently with radiation therapy for participants with Stage II or
III breast cancer who have undergone breast conserving surgery or mastectomy
This is a phase I dose escalation study of cisplatin and radiation to determine the toxicity
of this combined treatment and establish an MTD.
of this combined treatment and establish an MTD.
Inclusion Criteria:
- Primary tumor is triple negative breast cancer
- Breast-conserving surgery or mastectomy with surgical excision of all gross disease
with negative surgical margins
- Pathologic or clinical stage II or III disease
- At least 3 week interval from last chemotherapy administration/breast surgery to
radiation (no more than 8 weeks)
Exclusion Criteria:
- Pregnant or breastfeeding
- Prior radiation to breast or ipsilateral regional nodes
- Ongoing therapy with other investigational agents
- Hormonal therapy
- Significant co-morbidity
- Pathologic complete response following preoperative chemotherapy
- Biopsy proven metastatic disease
We found this trial at
5
sites
450 Brookline Ave
Boston, Massachusetts 2215
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Jennifer Bellon, MD
Phone: 617-632-3591
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
Boston, Massachusetts 02114
617-724-5200
Phone: 617-726-6500
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
Boston, Massachusetts 02115
(617) 732-5500
Principal Investigator: Jennifer Bellon, MD
Phone: 617-632-3591
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials